TITLE

The Landmark Surgical Trials of the National Surgical Adjuvant Breast and Bowel Project

AUTHOR(S)
Wickerham, D. Lawrence; Costantino, Joseph; Mamounas, Eleftherios P.; Julian, Thomas B.
PUB. DATE
July 2006
SOURCE
World Journal of Surgery;Jul2006, Vol. 30 Issue 7, p1138
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In this paper we provide a summary of several of the completed and ongoing surgical trials of the National Surgical Adjuvant Breast and Bowel Project, one of the cancer cooperative trials groups supported by the US National Cancer Institute.
ACCESSION #
21553383

 

Related Articles

  • NCI warning on tamoxifen.  // Drug Topics;12/11/95, Vol. 139 Issue 23, p8 

    Reports on the National Cancer Institute's recommendation to limit the use of tamoxifen in treating early breast cancer to five years in clinical practice. Possibility of continued use as detrimental to health.

  • Cancer institute to tighten control of trials. Gavaghan, Helen // Nature;4/21/1994, Vol. 368 Issue 6473, p679 

    Reports on the plan of the US National Cancer Institute (NCI) to strengthen its monitoring of clinic trials. Discovery of fraudulent data evaluating breast cancer treatment among women; Samuel Broder as director of the NCI; Lumpectomy trial as treatment for breast cancer; Alteration of records...

  • Tamoxifen `breakthrough' a bitter pill to swallow. Mitchell, Penni // Herizons;Summer98, Vol. 12 Issue 2, p9 

    Focuses on the controversy surrounding a National Cancer Institute study that hailed tamoxifen as a preventive treatment for women believed to be at high risk of getting breast cancer. Stand of breast cancer activists on the study; Results of the study done; Information on the cancer drug.

  • Workshop affirms value of breast conserving treatments. Smigel, Kara // JNCI: Journal of the National Cancer Institute;12/21/94, Vol. 86 Issue 24, p1824 

    Reports on the reaffirmation of breast-conserving therapy as an appropriate treatment for the early stages of breast cancer during a workshop sponsored by the US National Cancer Institute. Results of a US Government Accounting Office report confirming the use of the type of therapy; Recount of...

  • Treatment Adjuvant Therapy.  // Current Medical Literature: Breast Cancer;2003, Vol. 15 Issue 1, p20 

    Offers information on several studies on adjuvant breast cancer treatment. 'Duration of Adjuvant Chemotherapy for Breast Cancer: A Joint Analysis of Two Randomised Trials Investigating Three Versus Six Courses of CMF,' by M. Colleoni, et al; 'A Trial of Two Questions,' by T. Whelan; 'Randomized...

  • Les traitements néoadjuvants (hors cancer du sein inflammatoire). Ceugnart, Luc; Coudert, Bruno; Dalenc, Florence; Guinebretiere, Jean-Marc; Rouanet, Philippe; Toledano, Alain // Oncologie;Oct2011, Vol. 13 Issue 10/11, p658 

    No abstract available.

  • Precision medicine and personalized breast cancer: combination pertuzumab therapy. Reynolds, Kerry; Sarangi, Sasmit; Bardia, Aditya; Dizon, Don S. // Pharmacogenomics & Personalized Medicine;2014, Vol. 7, p95 

    Trastuzumab (Herceptin), a monoclonal antibody directed against the human epidermal growth-factor receptor 2 (HER2), is the poster child for antibody-based targeted therapy in breast cancer. Pertuzumab, another humanized monoclonal antibody, binds to a different domain of HER2 and prevents the...

  • Quality of Life at the End of Primary Treatment of Breast Cancer: First Results From the Moving Beyond Cancer Randomized Trial. Ganz, Patricia A.; Kwan, Lorna; Stanton, Annette L.; Krupnick, Janice L.; Rowland, Julia H.; Meyerowitz, Beth E.; Bower, Julienne E.; Belin, Thomas R. // JNCI: Journal of the National Cancer Institute;3/3/2004, Vol. 96 Issue 5, p376 

    Background: During the last decade, survival rates for breast cancer have increased as a result of earlier detection and increased use of adjuvant therapy. Limited data exist on the psychosocial aspects of the transitional period between the end of primary treatment and survivorship. We...

  • Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy ... Gnant, M.; Filipits, M.; Greil, R.; Stoeger, H.; Rudas, M.; Bago-Horvath, Z.; Mlineritsch, B.; Kwasny, W.; Knauer, M.; Singer, C.; Jakesz, R.; Dubsky, P.; Fitzal, F.; Bartsch, R.; Steger, G.; Balic, M.; Ressler, S.; Cowens, J. W.; Storhoff, J.; Ferree, S. // Annals of Oncology;Feb2014, Vol. 25 Issue 2, p339 

    We demonstrate that the PAM50 risk of recurrence score provides additional prognostic information for distant recurrences over standard clinical variables in the large clinical trial ABCSG-08. This molecular assay has been optimized to identify intrinsic breast cancer subtypes. This added...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics